Track CanSino Biologics's EBIT ($-52M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
The latest EBIT for 688185.SS is $-52M as of September 2026. That compares with $-230M in the prior-year period — up 77.8% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside CanSino Biologics's historical trend and sector peers before judging valuation or financial health.
Over the past year, 688185.SS's EBIT moved from $-230M to $-52M — a 77.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CanSino Biologics's operating scale or balance-sheet position.
Against Healthcare companies, 688185.SS currently prints $-52M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at CanSino Biologics's growth, margins, and balance sheet.
A EBIT figure of $-52M for 688185.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.
After noting 688185.SS's EBIT ($-52M), review year-over-year change from $-230M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.